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Abstract
Background: There is no effective treatment strategy for advanced castration-resistant prostate cancer. Although
Docetaxel (Taxotere
®) represents the most active chemotherapeutic agent it only gives a modest survival
advantage with most patients eventually progressing because of inherent or acquired drug resistance. The aims of
this study were to further investigate the mechanisms of resistance to Docetaxel. Three Docetaxel resistant sub-
lines were generated and confirmed to be resistant to the apoptotic and anti-proliferative effects of increasing
concentrations of Docetaxel.
Results: The resistant DU-145 R and 22RV1 R had expression of P-glycoprotein and its inhibition with Elacridar
partially and totally reversed the resistant phenotype in the two cell lines respectively, which was not seen in the
PC-3 resistant sublines. Resistance was also not mediated in the PC-3 cells by cellular senescence or autophagy but
multiple changes in pro- and anti-apoptotic genes and proteins were demonstrated. Even though there were
lower basal levels of NF-B activity in the PC-3 D12 cells compared to the Parental PC-3, docetaxel induced higher
NF-B activity and IB phosphorylation at 3 and 6 hours with only minor changes in the DU-145 cells. Inhibition of
NF-B with the BAY 11-7082 inhibitor reversed the resistance to Docetaxel.
Conclusion: This study confirms that multiple mechanisms contribute to Docetaxel resistance and the central
transcription factor NF-B plays an immensely important role in determining docetaxel-resistance which may
represent an appropriate therapeutic target.
Keywords: Docetaxel, Prostate, NF-?κ?B, Apoptosis, Viability
Background
Unfortunately there is no effective treatment strategy for
advanced castration-resistant prostate cancer [1,2].
Although Docetaxel (Taxotere
®) currently represents
the most active chemotherapeutic agent it only gives a
modest survival advantage with most patients eventually
progressing because of inherent or acquired drug resis-
tance. A number of mechanisms have been proposed to
contribute to this resistance. Firstly, the majority of
prostate tumours are slow growing even in metastatic
disease and thus are unlikely to respond to drugs that
are S phase-dependent [3]. Secondly, failure of che-
motherapy may be caused by reduced intracellular con-
centrations of a drug through either increased efflux or
decreased intake secondary to alterations in drug trans-
porters, particularly P-glycoprotein (P-gp). Multidrug
resistance (MDR) mechanisms including increased
expression of the P-gp or increased cellular metabolism
of drug detoxifying proteins, such as glutathione-S-
transferase, have been shown to protect the cancer cells
against cytotoxic drugs [4]. Thirdly, alterations in b-
tublin isotypes with different kinetics of microtubule
formation have been shown to contribute to resistance.
With an increase in isotypes III and IV correlating with
Docetaxel resistance in vitro [5]. Fourthly, mutations in
tumour suppressor proteins, such as loss of PTEN
which is a common event occurring in about 60% of
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phosphatidylinositol 3’-kinase (PI3K) signal transduction
cascade resulting in increased cellular proliferation and
survival mediated by AKT [6]. Finally, as the prostate
cancer phenotype progresses there is the expression of
survival factors that inhibits the apoptotic cell death
pathway [7], mediated in part by the activation of AKT
and other survival signalling pathways. Studies by our
group and others have identified elevated protein levels
of Bcl-2 [7], Inhibitors of Apoptosis proteins (cIAP-1,
cIAP-2, XIAP and Survivin) [8], Clusterin and Heat
Shock Proteins [9], as important anti-apoptotic proteins
in the development of resistance to a number of apopto-
tic triggers. However the identification and manipulation
of these multiple mechanisms represents a significant
challenge as targeting individual proteins has little clini-
cal impact. This was demonstrated in a recent phase II
clinical trial with oblimersen sodium, a Bcl-2 antisense
oligonucleotide and Docetaxel which did not achieve its
primary endpoint of reducing PSA and was associated
with increased toxicity [10]. However strategies to block
multiple Bcl-2 family members are under way with AT-
101, a small molecular inhibitor of Bcl-2, Bcl-xl, Bcl-w
and Mcl-1 (clinicaltrials.gov ID: NCT00571675).
Another approach to block multiple downstream
genes is to inhibit central transcription factors. There is
increasing evidence that inflammation drives the devel-
opment and progression of prostate cancer [11]. Nuclear
factor kappa B (NF-B) is a central transcription factors
activated by inflammation and other cells stresses
including paclitaxel [12]. Inhibition of NF-Bw i t h
CAPE increases caspase dependent cell death in PC-3
cells mediated via a reduction in IAP expression [12].
Indirect inhibition of NF-B with an IKK complex inhi-
bitor enhances Docetaxel induced apoptosis in PC-3 and
DU-145 cells [13].
This study was undertaken to further investigate the
mechanisms of resistance to Docetaxel. A number of
Docetaxel resistant sub-lines were generated in the
androgen-independent (PC-3, DU-145) and sensitive
(22RV1) cell lines. Resistance in the 22RV1 R cells was
explained via over expression of P-gp which could be
reversed by its inhibition. DU-145 cells have lower levels
of P-gp and the resistance was partially blocked by Ela-
cridar. PC-3 cells had no detectable levels of P-gp and
Elacridar had no effect on resistance to Docetaxel. Resis-
tance was also not mediated by cellular senescence or
autophagy in the PC-3 cells, but multiple changes in
pro- and anti-apoptotic genes and proteins were demon-
strated. Even though there were lower basal levels of
NF-B activity in the PC-3 D12 cells compared to the
Parental PC-3, docetaxel induced higher levels of NF-B
activity and IB phosphorylation with only minor
changes in the DU-145 cells. Inhibition of NF-Bw i t h
the BAY 11-7082 inhibitor reversed the resistance to
Docetaxel.
Materials and methods
Cell culture and resistant cell line development
The human prostate cancer cell lines PC-3, DU-145 and
22RV1 were purchased from the American Type Culture
Collection (ATCC) and maintained in RPMI-1640 med-
ium supplemented with 10% Fetal Bovine Serum (FBS),
50 U/ml penicillin/50 μg/ml streptomycin and 2 mM L-
glutamine (Invitrogen).
PC-3 resistant sub-lines were generated by initially
treating with Docetaxel (Sigma) at 4 nM and 8 nM (sus-
pended in dimethyl sulfoxide (DMSO) (Fluke)) in 75
cm
2 flasks for 48 hours. After treatment, the surviving
cells were re-seeded into new flasks and allowed to
recover for 2-3 weeks. After 5 (at 8 nM) and 7 (at 4
nM) treatments, the dose of docetaxel was increased
from 4 nM and 8 nM to 8 nM and 12 nM respectively.
The cells underwent a total of 18 treatment cycles at 8
nM and 12 treatment cycles at 12 nM, (cell passage
numbers 21-55). Following each treatment they were
allowed to fully recover before assessing their resistance
to docetaxel and any experimental work. As the passage
number of these treated cells increased over time, a sub-
set of PC-3 cells were aged alongside these cells as an
appropriate control to ensure that the effects seen were
due to resistance rather than due to an ageing effect of
the PC-3 cells (PC-3 Ag). In all subsequent experiments,
the resistant cells are referred to as PC-3 D8 and PC-3
D12 (reflecting the final treatment doses), and the age-
ing control cells are referred to as P-C3 Ag. Batches of
cells were frozen down and all experiments were carried
out on similar passages.
Docetaxel resistant cell lines (DU-145 R; 22RV1 R)
were developed over a period of 6 months by stepwise
increased concentrations of docetaxel. Cells were con-
tinuously maintained in docetaxel, with treatments
beginning at the initial IC50 of the respective parent cell
lines. Media containing docetaxel was changed every 2-3
days. As cells displayed resistance to treatments of doce-
taxel the concentration was subsequently increased with
final treatment doses of 100 nM. Resistance was judged
based on decreased cell death and increased prolifera-
tion of cells. Age-matched parent cells (DU-145 Ag;
22RV1 Ag) which did not receive treatment were also
maintained in culture. Batches of cells were frozen
down and all experiments were carried out on similar
passages.
Quantification of apoptosis and viability
Apoptotic events were described as a percentage of
total events with hypodiploid DNA assessed by propi-
dium iodide incorporation as previously described [14].
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with a hypotonic fluorochrome solution (50 mg/ml PI,
3.4 mM sodium citrate, 1 mM Tris, 0.1 mM EDTA,
a n d0 . 1 %T r i t o nX - 1 0 0 )a n di n c u b a t e do ni c ef o r1 0
minutes prior to analysis. Samples were run on a Beck-
man-Coulter FC-500 Cytometer. Ten thousand events
w e r eg a t e do nP Ii n t e n s i t ya n da n a l y s e du s i n gM p l u s
software.
NF-B Inhibitor
Cells (100,000 cells/well) were pre-treated with the NF-
B inhibitor, BAY 11-7082 (Merck), (5 μM) for 24
hours after which they were treated with docetaxel (20
nM) for a further 48 hours before been assessed for
apoptosis as previously described above.
P-glycoprotein Inhibitor
Cells (100,000 cells/well) were pre-treated with the P-
glycoprotein inhibitor, Elacridar (DCU), (0.25 & 0.5 μM)
for 24 hours after which they were treated with doce-
taxel (20 nM) for a further 48 hours before been
assessed for apoptosis as previously described above.
3-(4,5)-dimethylthiazol-2-yl-2,5-diphenyltetrazolium
bromide (MTT) assay cell viability assay
Cell viability was assessed by MTT cell staining as pre-
viously described [15]. Ten thousand cells/well were cul-
tured in a 96-well plate. Twenty-four hours later, cells
were treated with several concentrations of Docetaxel
( 1 0n M ,2 0n M ,5 0n Ma n d1 0 0n M )f o r2 4 ,4 8a n d7 2
hours. MTT (50 μl of a 5 mg/ml in PBS; Sigma-Aldrich)
was added to each well and the cells were incubated in
aC O 2 incubator at 37°C for 5 hours. Following media
removal, the MTT-formazan formed by metabolically
viable cells was dissolved in 200 μlo fD M S O( S i g m a -
Aldrich) and the absorbance was measured in a plate
reader at 550 nm.
Senescence-associated-ß-galactosidase activity
Senescence was assessed by staining cells for b-galacto-
sidase expression as previously described [16]. Briefly,
150,000 cells were seeded in 6 well/plates, 24 hours
later cells were treated with several concentrations of
Docetaxel for specific times as determined in the experi-
mental design. The cells were then washed twice with
PBS, fixed with 2% formaldehyde (Sigma) and 0.2% glu-
taraldehyde (Sigma-Aldrich) in water for 10 minutes
and washed again in 2 × PBS washes. Cells were stained
with X-gal staining solution (1 mg/ml X-gal, 40 mmol/l
citric acid/sodium phosphate pH 6, 5 mmol/l potassium
ferrocyanide, 150 mmol/l NaCl, 2 mmol/l MgCl2)f o r2 4
hours in a CO2 incubator at 37°C and then rinsed in 2
× washes of PBS and counted using a phase contrast
microscope (Olympus CK2). Senescent cells were
expressed as a percentage of the total number of cells
counted (300 cells/well).
RNA isolation, cDNA synthesis and Real-time RT-PCR
analysis using TaqMan Low Density Arrays
Total RNA was extracted using Trizol reagent (Invitro-
gen, Paisley, UK) using standard procedures as pre-
viously described [17]. The RNA was used to generate
cDNA as previously described [17]. PCR amplification
of cDNA template was performed in a thermal cycler
(Perkin Elmer 7700).
Pre-designed TaqMan probe and primer sets for target
genes were chosen from an on-line catalogue (Applied
Biosystems). Once selected, the sets were factory-loaded
into the 384 wells of TaqMan Low Density Arrays
(LDAs). The array format was customized on-line with
one replicate per target gene. Expression levels of target
genes were normalised to 18S rRNA (Additional file 1
lists the 95 genes chosen for inclusion, and their func-
tion). Samples were analyzed using the 7900HT system
with a TaqMan LDA Upgrade (Applied Biosystems),
according to the manufacturer’s instructions. In short,
single-stranded cDNA (to final concentration of 100 ng
as calculated from starting RNA) was combined with
water and TaqMan Universal PCR Master Mix, follow-
ing by loading 100 μl of each sample per port. Thermal
cycling conditions were as follows: 50°C for 2 min, 94°C
for 10 min, 97°C for 30 s, and 59.7°C for 1 min. Gene
expression values were calculated based on the ΔΔCt
method, where one sample was designated the calibra-
tor, through which all other samples were analysed.
Briefly, ΔCt represents the threshold cycle (Ct) of the
target minus that of 18S rRNA and ΔΔCt represents the
ΔCt of each target minus that of the calibrator. Relative
quantities were determined using the equation 2
-ΔΔCt.
For the calibrator sample (i.e. normal LCM tissue), the
equation is relative quantity = 2
-0, which is 1; therefore,
every other sample is expressed relative to this [18].
Total cellular protein isolation and western blotting
Whole cell lysates were extracted from treated cells
grown to 90% confluence on T75 flasks and 6-well
plates. Cells were washed in cold PBS (1100 rpm, 1 min,
4°C in a microcentrifuge) and resuspended in NP-40,
Tris 10 mM pH 8.0, 60 mM KCl, 1 mM EDTA pH 8.0,
1.0 mM DTT, 10 μl/ml Protease Inhibitor Cocktail
(Sigma P8340)/1 ml of lysis buffer and 10 mM PMSF.
Samples were then placed on ice for 10 mins and the
cell lysate collected after centrifugation (13000 rpm 5
mins at 4°C). Phosphorylated proteins were isolated
using the same protocol above with the addition of 10
μl Phosphatase Inhibitor Cocktail (Sigma P2850)/1 ml of
lysis buffer [18].
Total cellular protein was determined by means of the
Bradford Assay Protein Detection Kit (Bio-Rad). Equal
amounts of protein (50 μg) were subjected to SDS poly-
acrylamide gel electrophoresis on 8-12% gels before
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branes as previously described [14]. Western blotting
was performed using antibodies to Bax (1/1000, Upstate
Biotechnology), Bcl-xL (1/1000), Bcl-2 (1/500, BD Bios-
ciences), Bid (1/1000, Biosource), Clusterin (1/1000), Id-
1 (1/200, Santa Cruz), LC3 (1/1000) P-gp antibody
(Mdr-1 D11, 1/200, Santa Cruz), HSP 90 (1/500, Stress-
Marq Biosciences Inc.) and b-Actin (1/5000, Sigma), fol-
lowed by incubation with the appropriate horseradish
peroxidase-conjugated secondary antibodies (Cell Signal-
ing). Autophagy was assessed by western blotting, using
an antibody against the autophagy marker LC3 (1/1000,
Sigma-Aldrich). As a positive control for the induction
of autophagy, cells were starved for 2 hours in Earl’s
balanced salt solution (EBSS). Bafilomycin A1 (20 nM,
S i g m a )w a su s e da sa ni n h i b i t o ro fa u t o p h a g y .S i g n a l s
were detected using ECL™ (Pierce).
Assessment of NK-B
TransAM™ NF-B Family Transcription Factor Assay Kit
NF-B activity in nuclear extracts in the cell lines was
determined using the the TransAM™ NF-BF a m i l y
Transcription Factor Assay Kit (Active Motif, Belgium).
Cells were grown to confluency and nuclear extracts
prepared as per the TransAM™ Assay Kit manual.
Briefly, nuclear extracts were suspended in TransAM
lysis buffer and nuclear proteins (12 μgt o t a lp r o t e i n )
were incubated with immobilized oligonucleotides con-
taining the NF-B consensus DNA-binding site (5’-
GGGACTTTCC-3’) for 1 hour at room temperature.
After washing, 100 μlo fo n eo ft h ed i l u t e dN F Ba n t i -
bodies (1:1000 antibody in 1X Antibody Binding Buffer)
was added to each well being used, including blank
wells for 1 hour at room temperature. After 3 washes,
100 μl of horseradish-peroxidase-conjugated secondary
antibody (1:1000 dilutions) were added to each well for
1 hour at room temperature. The colourimetric sub-
strate was then added after 3 subsequent washes, and
the plate was allowed to develop for up to 5 minutes.
Following this, the reaction was stopped and absorbance
read at 450 nm on a SpectraMax M2 plate reader
(Molecular Devices, CA, USA). Relative activation of the
NF-B subunits between the three cell lines could then
be plotted, with an increase in absorbance being indica-
tive of increased activation.
NF-B Reporter assay
NF-B transcriptional activity was assessed using a plas-
mid containing the luciferase reporter gene regulated by
five copies of an NF-B responsive element (Promega).
A TK-Renilla luciferase plasmid was used as a transfec-
tion efficiency control. Plasmids were co-transfected
using GeneJuice
® Transfection Reagent (Novagen) fol-
lowing the manufacturer’s instructions. After 6 hours,
cells were treated with or without 50 nM of docetaxel,
for 3, 6 and 24 hours. The luciferase and renilla activ-
ities were measured using a Dual-Luciferase
® reporter
assay (Promega). The NF-B transcriptional activity was
expressed as fold change of Relative Luciferase Units
(ratio between luciferase light values divided by the
renilla light values), taking the untreated controls as the
baseline.
Statistical analysis
Statistical analysis was carried out using independent
samples student t-tests. Results were considered statisti-
cally significant where p < 0.05 and results are expressed
as mean ± the standard deviation.
Results
Effects of Docetaxel on (A) Apoptosis and (B) Proliferation
in the Docetaxel resistant sublines
Figure 1A demonstrates the apoptotic effects of two dif-
ferent concentrations of Docetaxel (20 nM and 80 nM)
for 48 hours on the four different Docetaxel resistant
s u b l i n e s .P C - 3D 8a n dP C - 3D 1 2d e m o n s t r a t e dp a r t i a l
but increasing resistance to docetaxel treatment over the
different doses, when compared to the PC-3 Ag. The
DU-145 R and 22RV1 R showed significantly more
resistance compared to the aged matched control cells
(DU-145 Ag & 22RV1 Ag). Cell viability was then deter-
m i n e db yt h eM T Ta s s a y( B ) ,f o l l o w i n gt r e a t m e n tw i t h
docetaxel (10 nM, 20 nM, 50 nM and 100 nM) for 24,
48 and 72 hours. The PC-3 Ag cells had an IC50@4 8
hrs = 10 nM, the PC-3 D8 an IC50@4 8h r s=2 0n M
and the PC-3 D12 an IC50@ 48 hrs = 100 nM following
treatment with Docetaxel (Figure 1B). This confirmed
that the PC-3 D8 and PC-3 D12 sublines had a resis-
tance to Docetaxel treatment.
P-glycoprotein (P-gp) expression in the Docetaxel
resistant sub-lines
We next wanted to investigate the mechanisms respon-
sible for Docetaxel resistance. We firstly examined the
expression of the classical drug pump, P-gp (Mdr-1) in
t h eP C - 3D 8a n dP C - 3D 1 2s u b l i n e sc o m p a r e dt ot h e
PC-3 Ag subline. Figure 2A clearly shows no expression
of P-gp in any of the PC-3 sublines, when compared to
the P-gp positive cell line (DLKP-A, Figure 2A), and the
DLKP negative cell line, as previously described [19].
We further confirmed P-gp was not playing a role in
this resistance by blocking P-gp activity with the P-gp
inhibitor, Elacridar (0.25 and 0.5 μM) [20,21]. Following
24 hours, pre-treatment, Elacridar had no effect on the
cells susceptibility to Docetaxel (20 nM) induced apop-
tosis over 48 hours. However, as a positive control the
P-gp over expressing cell line NCI/ADR/RES (ovarian
cancer cell line) underwent increased levels of apoptosis
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hours (Figure 2B).
Similar experiments were carried out with the DU-145
R and 22RV1 R sublines. Western blotting demonstrated
expression of P-gp in the DU-145 R and 22RV1 R sub-
lines with higher expression in the 22RV1 R (Figure
2C). Elacridar treatment (0.25 and 0.5 μM) also partially
reversed the resistance to apoptosis in the DU-145 R
cells and totally reversed the resistance in the 22RV1 R
sublines following treatment with Docetaxel (20 nM) for
48 hours (Figure 2D). As the resistance to Docetaxel
induced apoptosis may be partially explained by the
over expression of P-gp in the DU-145 R and 22RV1 R
cells we focused on the PC-3 D8 and PC-3 D12 sublines
whose resistance was not P-gp dependent.
Cellular senescence and autophagy as mechanisms of
Docetaxel resistance
Senescent cells demonstrate resistance to apoptosis and
express b-galactosidase. The effects of Docetaxel treat-
ment (100 nM for 48 hours) on PC-3 Ag, PC-3 D8 and
PC-3 D12 cellular senescence is demonstrated in Figure
3 which shows no significant increase in b-galactosidase
staining.
Autophagy (macroautophagy) is also a well conserved
mechanism by which cells adapt to stress such as starva-
tion [22]. This complex cellular process has recently
been associated with resistance to cancer therapies [23].
Total cellular protein was extracted from the different
cell lines following Docetaxel treatment (50 nM) and
assessed for the expression of LC3 II, a protein asso-
ciated with autophagosome formation and a marker of
autophagy [24]. While the resistant PC-3 D12 sub-lines
showed a higher baseline expression of LC3I, the pre-
cursor of LC3II, no consistent difference in the baseline
expression levels of LC3II was demonstrated between
the PC-3 Ag and the resistant PC-3 D12 subline (Figure
4) following treatment.
Altered expression of apoptotic related genes in the
Docetaxel resistant sublines
Having ruled out P-gp, senescence and autophagy as
possible mechanisms of resistance in the PC-3 resistant
sublines we next investigated other mechanisms and
focused on the alteration in genes and proteins which
regulate cellular apoptosis. Custom designed Low Den-
sity Arrays (LDA) which included the probes for the
IAPs, death receptors, death ligands, and signalling
molecules as well as genes involved in cell cycle regula-
tion, DNA damage and repair and chemotherapy resis-
tance were developed. Additional file 1, lists the 95
genes chosen for inclusion and their function.
Table 1 demonstrates the genes which were increased
in the PC-3 D8 subline compared to the PC-3 Ag cells.
The majority of these genes are anti-apoptotic including
BIRC7 (Livin-a member of the IAP family), Bcl2-A1
(Bcl-2 member), Foxo1A and HSP 90. Clusterin, a mole-
cular chaperone was also found to be increased. TNF
receptor family member 10C, which is known to inhibit
TRAIL-induced apoptosis, was also increased in this
subline. Nibrin and p73 which are involved in DNA
damage and repair were also up-regulated. Table 2
demonstrates the genes which were down-regulated in
 
 
Figure 1 Effects of Docetaxel on apoptosis and proliferation in
the PC-3, DU-145 and 22RV1 Docetaxel resistant sublines.A .
The PC-3 Ag, PC-3 D8, PC-3 D12, DU-145 Ag, DU-145 R, 22RV1 Ag
and 22RV1 R cell lines were treated with Docetaxel (20 and 80 nM)
for 48 hrs. Apoptosis was assessed by propidium iodide DNA
staining and flow cytometry. Values are expressed as mean ±
standard deviation. An independent samples t-test was used to
compare the mean percentage apoptosis for control, 20 nM and 80
nM for each cell line. **p < 0.001. B. Cell proliferation was measured
using the MTT Assay. The PC-3 sublines (PC-3 Ag, PC-3 D8 and PC-3
D12) were treated with increasing doses of Docetaxel (10, 20, 50 &
100 nM) for 24, 48 and 72 hrs. Data shown is representative of three
independent experiments.
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Page 5 of 13the PC-3 D8 subline compared to the PC-3 Ag cells. A
number of genes involved in the induction of apoptosis
were shown to be changed. These include; FOXO1,
NGFR, TRAF-1, and TRAF-2. Surprisingly a number of
anti-apoptotic genes were also decreased including;
MCL-1 and BIRC3.
Genes increased in the PC3-D12 subline compared to
t h eP C - 3A gc e l l sa r er e p r e s e n t e di nT a b l e3 .M a n yo f
the increased genes are anti-apoptotic genes such as
BIRC1, BCL2-A1, FOXO1A, NOL3 and Clusterin.
Genes involved in DNA damage and repair such as
Nibrin, Chek-1 and ATM were also increased.
Decreased gene expression in the PC3-D12 subline com-
pared to the PC-3 Ag cells is demonstrated in Table 4.
Many of these genes are those involved in the induction
of apoptosis. These include BOK, NGFR, Fas, FasLG,
TNF receptor member 11b, TRAF-1 and TRAIL. A
number of genes involved in cell cycle regulation and
DNA damage detection were also decreased. These
include Chek2, p21, ETS2 and ATR.
Validation of altered gene expression
We next wanted to validate specific genes at the protein
level. Total cellular protein was extracted from the PC-3
Ag, PC-3 D8 and PC-3 D12 and assessed by western
blotting for Clusterin, Id-1, Bcl-2, Bcl-xL, Bid and Bax.
As demonstrated in Figure 5, Id-1 expression was
increased in the PC-3 D12 subline only, while the pro-
tein expression of Bcl-2 was increased in PC-3 D8 but
not in PC-3 D12. Anti-apoptotic Bcl-xL was increased
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Figure 2 P-gp expression levels in the Doctaxel resistant cell lines. A. Total cellular protein was extracted from the cells and 50 μgw a s
assessed by western blotting. P-gp was not expressed in the PC-3 Ag, PC-3 D8, PC-3 D12 sublines or the DLKP (40 μg) negative control cell line,
but was expressed in the DLKP-A (5 μg) drug resistant variant of the DLKP cell line. b-actin the house keeping protein was used as loading
control for P-Gp. B. The PC-3 Ag, PC-3 D12 and NCI-ADR/RES cells lines were treated with Docetaxel (20 nM) alone or in the presence of the P-
gylcoprotein inhibitor Elacridar (0.25 and 0.5 μM) and Docetaxel (20 nM) and assessed for apoptosis by flow cytometry. An independent samples
t-test was used to compare the average percentage of apoptosis between the control groups and each of the treated groups for the PC-3 Ag,
PC-3 D12 and NCI-ADR/RES cell lines *p- < 0.05. C. Total cellular protein was extracted from the cells and 50 μg was assessed by western
blotting. P-Gp was weakly expressed in the DU-145 R and strongly expressed in the 22RV1 R sublines. No expression was seen in the Aged
matched. b-actin the house keeping protein was used as loading control for p-glycoprotein. D. The DU-145 Ag, DU-145 R and 22RV1 Ag and
22RV1 R cells lines were treated with Docetaxel (20 nM) alone, or the P-Gp inhibitor Elacridar (0.25 μM) alone or in the presence of Elacridar
(0.25 μM) and Docetaxel (20 nM) and assessed for apoptosis by flow cytometry. Blots shown are representative of three independent
experiments.
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decreased in PC-3 D12 while Bax was decreased in both
sublines. Clusterin was significantly increased in both
sublines. The molecular chaperone HSP90 was also
increased in both sublines (Figure 5).
Docetaxel treatment increases NF-B activity in the PC-3
D12 resistant PC-3 subline
As NF-B regulated the expression of a number of the
apoptotic genes listed in Tables 1, 2, 3 and 4, we next
Control                     100 nM Docetaxel
PC-3 Ag
PC-3 D8
PC-3 D12
0.4% (2/485) 0.6% (2/318)
0.7% (2/276) 1% (1/100)
1.1% (3/267) 1.4% (5/350)
Figure 3 Cellular sensecence in response to Docetaxel
treatment. The PC-3 Ag, PC-3 D8 and PC-3 D12 cells were plated
in 6 well plates at 300,000/well and grown for 24 hours. The cells
were then treated with Docetaxel (100 nM) for 48 hours and fixed
with 2% formaldehyde and 0.2% glutaraldehyde. Senescent cells
were then assessed by staining cells for b-galactosidase expression.
Positive cells were counted and expressed as a percentage of the
total number of cells in the well. Pictures are a representation of 5
independent experiments.
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Figure 4 Autophagy as a mechanisms of Docetaxel resistance.
Following treatment of the Aged matched controls (Upper panel)
and PC-3 D12 resistant sublines (Bottom panel) with 50 nM of
Docetaxel for 1, 3, 6, 12 and 24 hrs, total cellular protein was
extracted and assessed for LC3II by western blotting using the
relevant anti-body and conditions as described in the methods
section. For positive controls cells were either treated with
Rapamycin (R, 0.2 μM) for 4 hrs, Starvation (S, the cells were starved
in EBSS (Earls Balanced Salt Solution) medium for 2 hrs), or
Starvation plus Bafilomycin (S+B, 20 nM) for 2 hrs. b-actin the house
keeping protein was used as loading control. Blots shown are
representative of three independent experiments.
Table 1 Genes increased in the PC-3 D8 Docetaxel
Resistant Cell line
PC-3 D8 vs PC-3 Ag Gene
Name
Accession no. Fold
change
p value
BIK NM_001197 4.606724005 0.024378
FOXO1 NM_002015 4.092077589 0.006372
NAIP NM_004536 3.895819042 NA
HSP90AA1 NM_001017963 2.255183574 0.116769
IL8 NM_000584 2.194814925 0.060076
BCL2A1 NM_001114735 2.003718027 0.018472
NBN NM_002485 1.994366021 0.011912
TNFRSF10C NM_003841 1.931533233 0.288353
TP73 NM_001126240 1.785086313 0.082871
BNIP3L NM_004331 1.747205486 0.03454
CLU NM_001171138 1.740002897 0.304795
APAF1 NM_001160 1.673345235 0.38724
FASLG NM_000639 1.563978305 0.73945
BNIP3 NM_004052 1.50139036 0.173556
Pre-designed TaqMan probe and primer sets for target genes were chosen
from an on-line catalogue (Applied Biosystems). Expression levels of target
genes were normalised to concentration of 18S rRNA (Additional File 1 lists
the 95 genes chosen for inclusion and their function). Total mRNA was
extracted from the PC-3 Ag and PC-3 D8 cells and used on custom designed
Low Density Arrays (LDA) to determine which genes were increased (fold
increase > 1.5) in the Docetaxel resistanct PC-3 D8 subline compared to the
PC-3 Ag. n = 3.
Table 2 Genes decreased in the PC-3 D8 Docetaxel
Resistant Cell line
PC-3 D8 vs PC-3 Ag
Gene Name
Accession no. Fold change p value
BAG1 NM_001172415 0.485055 0.102992
MCL1 NM_021960 0.464403 0.048121
ID1 NM_002165 0.460689 0.434385
ATR NM_001184 0.435832 0.039411
PTEN NM_000314 0.422497 0.245383
NGFR NM_002507 0.391286 0.285516
BNIP2 NM_004330 0.36245 0.124787
JUN NM_002228 0.339603 0.18277
BIRC3 NM_001165 0.313233 0.006408
BMF NM_001003940 0.292831 0.104867
DDIT3 NM_001195053 0.279562 0.157249
TRAF1 NM_001190945 0.269089 0.18055
IL6 NM_000600 0.190685 0.031992
IGF1R NM_000875 0.160304 0.013039
MAPK10 NM_002753 0.123932 NA
TNFSF10 NM_001190942 0.115113 0.175825
BIRC8 NM_033341 0.024782 0.517705
TNFRSF10D NM_003840 0.011276 0.144385
Genes whose expression has decreased (fold increase <0.5) in the Docetaxel
resistant PC-3 D8 subline compared to the PC-3 Ag. n = 3.
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Page 7 of 13wanted to determine whether NF-B played a role in
the resistance to Docetaxel. We firstly assessed the base-
line transcriptional activity in the PC-3 resistant subline
using a luciferase assay. Interestingly, NF-Bt r a n s c r i p -
tional activity was significantly decreased (p < 0.001) in
the resistant PC-3 D12 subline compared to the PC-3
Ag cells (Figure 6A). The DU145 cell lines showed a
similar trend with decreased NF-B transcriptional
activity in the resistant subline (DU-145 R) compared to
the parental (DU-145 Ag); while there was no difference
in NF-B activity in the aged (22RV1 Ag) matched and
resistant 22RV1 (22RV1 R), being the baseline NF-B
activity in these cells was very low in comparison to the
PC-3 and DU145 cells (data not shown). NF-B
decreased activity in the resistant PC-3 sublines was
confirmed by the TransAM ELISA based assay which
showed a significant decrease in the activity of p52 (p <
0.01) and RelB (p < 0.05) subunits, in both the PC-3 D8
and PC-3 D12 resistant cells compared to the PC-3 Ag
(Figure 6B).
We then assessed the effects of Docetaxel treatment
on NF-B transcriptional activity in the resistant sub-
line. Following Docetaxel treatment there was signifi-
cantly increased transcriptional activity in the PC-3
D12 resistant subline compared to the PC-3 Ag cells
( F i g u r e7 A ) .T h e r ew a sn oi n c r e a s ei nt h eD U - 1 4 5R
subline (Figure 7A), and there was no NF-B activity
in the 22RV1 cells neither in response to docetaxel or
to the classical NF-Bi n d u c e r ss u c ha sT N F a or LPS
(data not shown). Activation of NF-Bi nt h er e s i s t a n t
PC-3 D12 subline compared to the PC-3 Ag cells was
confirmed by western blotting showing higher levels of
phospho-IBa in the PC-3 D12 compared to the PC-3
Ag, following 3-6 h of docetaxel treatment (Figure 7B).
NF-B was functionally confirmed to be centrally
involved in resistance to Docetaxel using the NF-B
inhibitor (BAY 11-7082, Merck) which reversed resis-
tance in both the PC-3 D8 and PC-3 D12 sublines
(Figure 8).
Discussion
The treatment of advanced prostate cancer represents a
significant challenge due to the accumulation of multi-
ple mechanisms of drug resistance. Resistance to Doce-
taxel treatment includes changes in classical multiple
drug resistant pathways, expression of different b-tublin
isotypes, mutations in tumour suppressor proteins and
altered expression of pro- and anti-apoptotic proteins
[25]. We have generated three models of docetaxel-
resistance in prostate cancer cells which may mimic the
Table 3 Genes increased in the PC-3 D12 Docetaxel
Resistant Cell line
PC-3 D12 vs PC-3 Ag Gene
Name
Accession no. Fold
change
p value
NAIP NM_004536 28.14023 NA
BCL2A1 NM_001114735 9.956213 7.84E-06
CLU NM_001171138 6.138126 0.019757
TNFRSF1B NM_001066 4.568718 NA
ATM NM_000051 2.884063 0.013665
FOXO1 NM_002015 2.746056 0.0167
MAP2K4 NM_003010 2.456245 0.13486
APAF1 NM_001160 2.264102 0.34641
NOL3 NM_001185057 1.946074 0.101148
CHEK1 NM_001114121 1.554884 0.433367
BNIP3L NM_004331 1.514918 0.113779
NBN NM_002485 1.505995 0.051555
Total mRNA was extracted from the PC-3 Ag and PC-3 D12 cells and used on
custom designed Low Density Arrays (LDA) which included the transcriptional
profile probes for the IAPs, death receptors, death ligands, and signalling
molecules as well as genes involved in cell cycle regulation, DNA damage and
repair and chemotherapy resistance. Additional File 1, lists the 95 genes
chosen for inclusion, and their function. Genes whose expression has
increased (fold increase > 1.5) in the Docetaxel resistanct PC-3 D12 subline
compared to the PC-3 Ag. n = 3.
Table 4 Genes decreased in the PC-3 D12 Docetaxel
Resistant Cell line
PC-3 D12 vs PC-3 Ag Gene
Name
Accession no. Fold
change
p value
XIAP NM_001167 0.481312 0.176898
CHEK2 NM_001005735 0.475224 0.131629
JUN NM_002228 0.46633 0.309774
BCL2L2 NM_004050 0.45255 0.082823
TRAF2 NM_021138 0.443326 0.006969
DDIT3 NM_001195053 0.432559 0.452576
BCL2L11 NM_006538 0.432054 0.074605
CDKN1A NM_000389 0.42579 0.080132
ETS2 NM_005239 0.382415 0.00487
IL8 NM_000584 0.369938 0.022567
FAS NM_000043 0.336752 3.61E-05
ATR NM_001184 0.315906 0.010488
BOK NM_032515 0.298213 0.014457
NGFR NM_002507 0.289875 0.003775
ABCB1 NM_000927 0.254066 NA
FASLG NM_000639 0.251687 0.330804
BIK NM_001197 0.249128 0.04058
XAF1 NM_017523 0.196716 0.637745
VEGFA NM_001025366 0.147831 0.017993
TRAF1 NM_001190945 0.13621 0.030832
BIRC3 NM_001165 0.102653 0.000293
TNFRSF11B NM_002546 0.099691 0.005951
TNFRSF10D NM_003840 0.085696 0.332193
EGR1 NM_001964 0.0682 0.005374
TP73 NM_001126240 0.026123 0.004742
BIRC8 NM_033341 0.024998 0.523298
TNFSF10 NM_001190942 0.01728 0.053714
IL6 NM_000600 0.011894 0.000652
Genes whose expression has decreased (fold increase <0.5) in the Docetaxel
resistanct PC-3 D12 subline compared to the PC-3 Ag. n = 3.
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Page 8 of 13situation in the clinical setting and used them to
understand the complexity of mechanisms leading to
treatment resistance. Understanding these pathways
will be essential if we want to better impact on the
outcome of these patients and identify additional co-
treatments which will manipulate this resistance and
develop personalised treatments. We demonstrated
that all four sublines are resistant to increasing con-
centrations of Docetaxel as assessed by apoptosis and
viability assays.
One of the main mechanisms of resistance to Doce-
taxel is the over expression of P-gp [4] which would
reduce intracellular concentrations of the drug through
increased efflux. Chemoresistant PC-3 cells do not over
express P-gp, while resistant DU145 cells exhibit both
over expression of the protein and restored chemosensi-
tivity with P-gp inhibition [5,26]. This has been the
basis for the development of cabazitaxel which can over-
come P-gp over expression [27] and is now used as a
second line therapy for patients who fail Docetaxel
treatments. In our study we demonstrated that the resis-
tance in the PC-3 D8 and PC-3 D12 sublines was inde-
pendent of P-gp over expression as there were no
detectable levels and no effects of the P-gp inhibitor Ela-
cridar on their resistance. However the DU-145 and
22RV1 cells expressed increasing levels of P-gp and Ela-
cridar totally reversed the resistance in the 22RV1 and
partially in the DU145 resistant sublines. Based on these
results we focused on the PC-3 cells to understand the
mechanisms of resistance independent of P-gp.
Bcl-xL
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Bcl-2
Bid
E-actin
E-actin
E-actin
E-actin
E-actin
Clusterin
HSP90
E-actin
E-actin
Ag D8 D12
PC-3
Figure 5 Validation of Low Density Arrays. Total cellular protein
was extracted from the PC-3 sublines (PC-3 Ag, PC-3 D8 & PC-3
D12) and 50 μg was loaded onto a western blot to assess the
expression of Clusterin, HSP90, Id-1, Bcl-2, Bcl-xL, Bax, and Bid using
their respective antibodies as described in the Method section. The
house keeping protein b-actin was used as a loading control. Blots
shown are representative of three independent experiments.
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Figure 6 NF-B transcriptional activity and Baseline NFkB
subunit activity. A. PC-3 Ag and PC-3 D12 cells were plated at
100,000/per well and grown for 24 hours. The baseline NFB activity
was assessed by luciferase assay, using a Dual Luciferase Assay from
Promega following the manufactures instructions. Averages from 3
independent experiments are shown. Mean values were compared
using t-test assuming equal variances. B. The PC-3 Ag and PC-3 D12
cells were grown to confluency and nuclear extracts prepared as
per the TransAM™ Assay Kit manual. Averages from 3 independent
experiments are shown. Mean values were compared using t-test
assuming equal variances.
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Page 9 of 13We next investigated cellular senescence as a possible
mechanism of resistance. Premature cellular senescence,
a phenomenon by which cells stop dividing and acquire
a typical morphology and an altered gene expression
profile in response to stress [3], has recently been asso-
ciated with chemotherapy resistance. We performed a
ß-galactosidase assay to assess cellular senescence fol-
lowing docetaxel treatment. Although ß-galactosidase
NFNB inhibitor (5μM)
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Figure 8 NF-B inhibitor studies following docetaxel treatment. The PC-3 sublines where pre-treated with the NFB inhibitor (BAY 11-7082,
5 μM) for 24 hours followed by Docetaxel (20 nM) for a further 48 hours and assessed for apoptosis by flow cytometry. Graphs represent the
results of 3 independent experiments. Mean values were compared using t-test assuming equal variances. * p < 0.05.
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Figure 7 NF-B transcriptional activity following docetaxel treatment. A. The PC-3 and DU-145 aged matched and Docetaxel resistant
sublines were treated with 50 uM concentrations of Docetaxel for 3, 6 and 24 hours at which time NFB activity was assessed by luciferase
assay, using a Dual Luciferase Assay from Promega following the manufactures instructions. Graphs are generated from 3 independent
experiments. Mean values were compared using t-test assuming equal variances. * p < 0.01; ** p < 0.0001. B. Cells were treated as above and at
the different time points total cellular protein was extracted and 50 ug loaded onto western blots and assessed for P-IkBa and IkBa. b-actin was
used as an additional loading control. Blots are representative of three independent experiments.
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Page 10 of 13staining showed a modest increase in the percentage of
senescent cells following docetaxel treatment, this
increase was considered to be insufficient to explain the
resistance of the PC-3 D8 and PC-3 D12 sublines to
docetaxel.
Autophagy (macroautophagy), a well conserved
mechanism by which cells adapt to stress such as starva-
tion, has also been recently associated with resistance to
cancer therapies [23]. Therefore we investigated whether
increased autophagy was involved in the resistance to
docetaxel in the PC-3 D12 subline. Although western
blotting showed increased expression of the autophagic
marker LC3II in the PC-3 D12 compared to the PC-3
Ag cells following docetaxel treatment, this was only a
modest effect. Interestingly, the resistant PC-3 D12 sub-
line showed a higher baseline expression of LC3I, the
precursor of LC3II, which warrants further investigation.
We next undertook to assess alterations in the apop-
totic phenotype of the resistant cells in order to under-
stand the mechanisms involved. Custom-designed LDA
containing real-time PCR assays for all the key apoptotic
genes including the IAPs, death receptors, death ligands,
and signalling molecules as well as genes involved in
cell cycle regulation, DNA damage and repair were
developed. The LDA results showed a complex interplay
between changes in the expression of both pro- and
anti-apoptotic proteins. From our study, genes which
were shown to be altered in both the docetaxel-resistant
sublines (PC-3 D8 and PC-3 D12) included; FOXO1,
NGFR, TRAF-1, Mcl-1, BIRC3, BIRC1, Bcl-2-A1, NOL3,
Clusterin, BOK, NGFR, Fas, FasLG, TNF receptor mem-
ber 11b and TRAIL.
Trougakos et al demonstrated that secreted clusterin
(sCLU) knockdown in human prostate cancer cells
induces significant reduction of cellular growth and
higher rates of spontaneous endogenous apoptosis [28].
sCLU is a cytoprotective chaperone that stabilizes con-
formations of proteins during times of cellular stress,
thereby inhibiting protein aggregation and precipitation
[29]. Additionally, sCLU can interact with and inhibit
activated Bax, thereby inhibiting cytochrome C release
and caspase activation [30]. In prostate cancer, sCLU
levels have previously been correlated with Gleason
grade [31]. A recent publication identified sCLU to be
over-expressed in a docetaxel-resistant PC-3 subline and
reported that knockdown of sClu chemosensitizes this
cell line to taxane and mitoxantrone based chemother-
apy both in vitro and in vivo [32].
Bcl-2 related protein A1 (Bcl2-A1) or BLF1 is a mem-
ber of the Bcl-2 family. Although it is regulated differ-
ently from Bcl-2, it has similar anti-apoptotic activity. A
recent publication demonstrated that Bcl2-A1 mediates
resistance to doxorubicin in haematopoietic cell lines
[33].
Modur et al found that FOXO1A was highly
expressed in normal prostate. They also noted that in
PTEN-deficient prostate carcinoma cell lines, FOXO1A
was cytoplasmically sequestered and inactive and
expression of TRAIL, a pro-apoptotic effector, was
decreased. They determined that TRAIL is a direct tar-
get of FOXO1A, and they hypothesized that the loss of
PTEN contributes to increased tumour cell survival
through decreased transcriptional activity of FOXO1A
and FOXO3A followed by decreased TRAIL expression
and apoptosis [34].
BNIP3L which is also elevated in both sublines, plays
ap r o - s u r v i v a lr o l ei na p o p t o s i s .Y a s u d aet al showed
that in vitro translated BNIP3L binds specifically and
directly with GST fusion proteins of various Bcl-2 family
anti-apoptosis proteins, suggesting that, like BNIP3,
BNIP3L may antagonize the activity of Bcl-2 family anti-
apoptosis proteins [35]. In this setting, BNIP3L may be
increased in our resistant sublines in an attempt to
antagonize the very elevated levels of Bcl2-A1.
Genes down-regulated in both sublines include
TRAIL, NGFR, TNF member 10D and ATR among
others (see Tables 1, 2, 3 and 4 results). As PC-3 cells
are highly resistant to TRAIL, it is unsurprising that
levels of pro-apoptotic TRAIL are further decreased in
the resistant sublines. Tumour necrosis factor superfam-
ily member 10D (TNF member 10D) has been shown to
act as a decoy receptor for TRAIL (TRAIL R4). Transi-
ent over-expression of TRAIL R4 in cells normally sen-
sitive to TRAIL-mediated apoptosis conferred complete
protection, and Degli-Esposti et al suggested that one
function of TRAIL R4 may be the inhibition of TRAIL
cytotoxicity [36]. As a large number of genes were either
increased or decreased in the docetaxel-resistant sub-
lines, targeting these individually may not lead to altera-
tions in the resistant phenotype but understanding the
central signalling pathways and transcription factors
would represent a more appropriate therapeutic target-
ing approach.
NF-B initiates the transcription of a wide variety of
genes that code for angiogenic factors, cell adhesion
molecules, anti-apoptotic factors, and cytokines, which
are involved in cell survival, invasion, metastasis, and
chemoresistance [37]. In addition to its role in oncogen-
esis, NF-B has been associated with chemoresistance in
various models [38-40]. Recent focus on inhibition of
NF-B activity has identified a sensitisation to apoptosis
induced by various apoptotic triggers, including Doce-
taxel in multiple cell lines including PC-3 cells [41]. Our
low density array studies identified the up-regulation of
a number of target genes of NF-B (IAPs, IL-8, TNF
receptor family members and FasLG). Based on these
findings we focused our investigations towards the cen-
tral role of NF-B in mediating the resistant phenotype.
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Page 11 of 13Despite a decrease in the baseline expression levels of
the NF-B subunits p52 and RelB and transcriptional
activity, when the cells were treated with Docetaxel
there was an increase in NF-B transcriptional activity.
This led us to the inhibition of NF-B activity using the
NF-B inhibitor BAY11-7082 prior to treatment with
Docetaxel which resulted in significant reversal of Doce-
taxel resistance.
Conclusion
A mounting body of evidence implicates dysregulation
of cell-survival signalling pathways in the pathogenesis
of castration-resistant prostate cancer. What is not clear
is which are the most salient targets in these pathways
that when inhibited will lead to reversal of resistance
and the most effective clinical outcome. An improved
understanding of the molecular mechanisms regulating
castration-resistant prostate cancer will drive both the
identification of appropriate treatment strategies and
biomarkers to inform such strategies. Our current
results indicate that NF-B plays an important role in
determining Docetaxel resistance and attempts to sensi-
tise resistant prostate cancer cells to Docetaxel therapy
should target this transcription factor.
Additional material
Additional file 1: List of genes on the Low Density Arrays. This table
contains the list of 95 genes contained on the Low Density Arrays
including gene name, gene symbol and gene function for each gene
included on the array.
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